Renexxion logo — company profile

Renexxion

Founded 2014 2-10 employees Venture round Biotechnology, Pharmaceutical

General Information

Company Name Renexxion
Founded Year 2014
Employees 2-10
Industries Biotechnology, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Renexxion. To contact Renexxion, visit renexxion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Renexxion compare?

A PDF of Renexxion and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Renexxion soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Renexxion

Renexxion is a biotechnology and pharmaceutical startup founded in 2014 that is working to address the unmet medical needs of patients struggling with functional gastrointestinal disorders. The company is focused on the development of Naronapride, an advanced-stage, Phase-3 ready, oral gastro-prokinetic drug within the 5-HT4 agonist category. This drug has shown efficacy across a variety of gastrointestinal conditions. Renexxion secured a Venture Round investment on 01 January 2017, with Atheneos Capital as the investor. The potential of Naronapride and its ability to meet the medical needs of a significant patient population position Renexxion as a promising player in the biotechnology and pharmaceutical industries.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 1
Atheneos Ventures
01 Jan 2017

Renexxion Alternatives & Competitors

View All Alternatives
Renexxion vs

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
Renexxion vs

Developing accessible oral small molecule therapies for the treatment of chronic diseases including...

IPO
219 employees
Biotechnology, Health Care
Renexxion vs

Developing innovative pharmaceuticals for hematological malignancies and disorders

Series C
3 employees
Biotechnology, Health Care

FAQ About Renexxion

Patients struggling with functional gastrointestinal disorders face a significant unmet medical need. Naronapride, an advanced-stage, Phase-3 ready, oral gastro-prokinetic drug within the 5-HT4 agonist category, has demonstrated efficacy across a variety of these conditions.
Renexxion was founded in 2014.
Renexxion operates in Biotechnology and Pharmaceutical.
Renexxion has approximately 2-10 employees.
Renexxion has completed 1 funding round. The latest funding stage is Venture round.
Top alternatives and competitors to Renexxion include Entero Therapeutics (Nasdaq: ENTO), Structure Therapeutics, Biosight Ltd., Zai Lab, Verdiva Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Renexxion and Entero Therapeutics (Nasdaq: ENTO) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Renexxion, https://bouncewatch.com/company/renexxion, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes